Back to mobile site

Stifel Reiterates Buy Rating on Relay Therapeutics (RLAY)

September 16, 2024 6:45 AM EDT Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $28.00 price target on Relay Therapeutics (NASDAQ: RLAY).The analyst commented: "Exiting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login